NCT07133438View on ClinicalTrials.gov

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

July 31, 2027

Conditions
Retinal Vein Occlusion (RVO)
Interventions
DRUG

Anti-VEGF drug

conventional anti-VEGF therapy (intravitreal injections of conbercept 0.5 mg initially once a month for 3 months, followed by on-demand therapy which based on recurrence criteria)

DRUG

Mecobalamin 5 MG

oral mecobalamin capsules 0.5 mg three times daily for 6 months

DRUG

Placebo

placebo capsule with a similar appearance and odor to the mecobalamin capsules three times daily for 6 months

Trial Locations (1)

400016

No. 1, Friendship Road, Yuanjiagang, Yuzhong District, Chongqing City, Chongqing

All Listed Sponsors
lead

First Affiliated Hospital of Chongqing Medical University

OTHER